Maravai Lifesciences Holdings (MRVI) FCF Payout Ratio (2020 - 2024)

Maravai Lifesciences Holdings (MRVI) posted quarterly FCF Payout Ratio of 0.01 for Q4 2024, down 111.19% quarter-over-quarter from 0.11 in Q2 2024.

Maravai Lifesciences Holdings (MRVI) FCF Payout Ratio (2020 - 2024) Analysis & Trends

Maravai Lifesciences Holdings' FCF Payout Ratio history runs 5 years deep, the most recent figure standing at 0.01 for Q4 2024.

In Q4 2024, FCF Payout Ratio changed N/A year-over-year to 0.01; the TTM figure through Sep 2025 stood at 0.02 (down 256.43% YoY), while the FY2024 annual figure was 0.1, up 31.72% from the prior year.
FCF Payout Ratio for Q4 2024 stood at 0.01, down from 0.11 in the prior quarter.
The five-year high for FCF Payout Ratio was 1.7 in Q4 2020, with the low at 0.22 in Q2 2023.
The 5-year median for FCF Payout Ratio is 0.25 (2022), against an average of 0.39.
The sharpest annual moves came in 2021 and 2023: FCF Payout Ratio soared 15966.18% in 2021, then sank 184.44% in 2023.
Maravai Lifesciences Holdings' FCF Payout Ratio stood at 1.7 in 2020, then declined by 1.4% to 1.67 in 2021, then sank by 82.96% to 0.28 in 2022, then slumped by 178.09% to 0.22 in 2023, then soared by 94.65% to 0.01 in 2024.
Business Quant data shows MRVI's FCF Payout Ratio at 0.01 in Q4 2024, 0.11 in Q2 2024, and 0.22 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Cover (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.17
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.07
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Maravai Lifesciences Holdings	1.48 Bn	1.56 Bn	20.65 Mn	-

Download Data